Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood test reveals how aging and chronic illness weaken immunity in the elderly

NCT ID NCT06513520

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the immune system changes in elderly people over 75 who have multiple chronic health problems. Researchers measured a specific immune marker (mHLA-DR) from a simple blood sample to understand the combined effects of aging and chronic diseases. The goal was to gather initial data to help improve care for this complex patient group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

81 people

The number who actually took part.

Started

Jan 2025

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will focus on polypathological patients aged over 75 hospitalised in a geriatric ward.

Ages

75 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For all patients: * Patients aged over 75 hospitalised in one of the geriatric units defined as the research sites; * Patient affiliated to a social security scheme; * Patients or relatives who have been informed and have no objections to the research. To be eligible in the acute situation sub-population: \- Patients presenting with an acute episode on admission or following a stay in the research sites; The acute episode is defined, for example, by an infection, cardiac decompensation, a complicated fall, acute renal failure, any acute or decompensated cardiovascular pathology, any discovery of cancer that has not been stabilised. To be eligible in the stable situation sub-population: \- A patient who has not had an acute episode for at least 7 days. Exclusion Criteria: For all patients: * Patients under legal protection: curatorship, guardianship, safeguard of justice ; * Patients under exclusive comfort care for whom it has been decided not to take a blood sample; * Patients undergoing long-term antibiotic treatment, i.e. with no defined stopping date; * An immunocompromised patient or a patient undergoing immunosuppressive treatment (for example: HIV infection, a patient awaiting solid organ transplantation, a patient undergoing haematopoietic stem cell transplantation, a patient undergoing chemotherapy for a solid tumour or haematological malignancy, a patient suffering from an auto-immune disease and being treated with immunotherapy and/or immunosuppressive therapy and/or biotherapy, an asplenic or hyposplenic patient, a patient undergoing experimental potentially immunosuppressive treatment, a patient undergoing Eculizumab treatment, a patient presenting a hereditary immune deficiency). For patients in an acute clinical situation: \- Patient previously included in the same sub-population.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Immune system are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Croix Rousse hospital

    Lyon, 69004, France

  • Dugoujon Hospital

    Caluire-et-Cuire, 69300, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.